NCT05571059

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2024-01-31Est. Completion: 2028-01

Enrollment target: 128 participants

Locations

Biosolutions Clinical Research, La Mesa, California, United States
University of California San Francisco, San Francisco, California, United States
UConn Health, Farmington, Connecticut, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Miami VA Health System, Miami, Florida, United States
Northwestern Medicine, Chicago, Illinois, United States
Indiana University Health, Indianapolis, Indiana, United States
University of Kansas, Kansas City, Kansas, United States
University of Louisville, Louisville, Kentucky, United States
Beaumont Hospital, Royal Oak, Royal Oak, Michigan, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
University of Rochester, Rochester, New York, United States
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Bend Memorial Hospital, Bend, Oregon, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
Avera Research Institute, Sioux Falls, South Dakota, United States

Interstitial Lung DiseaseChronic Obstructive Pulmonary DiseaseHypoxemia

Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung dise…

Buffalo, United StatesCompleted Oct 2027

Idiopathic Pulmonary Fibrosis

This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF)…

Tucson, United StatesEst. completion Mar 15, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.